Inhibrx INBRX-106 nears doubles response in Phase 2 HNSCC
Inhibrx reports INBRX-106 nearly doubles response rate and interim median PFS of 9.6 months in its Phase 2 HNSCC study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.